Pharma MarXMAD:PHM +1.11%86 ROE % is 2.45% as of Mar. 2026, which is 64% below its 10-year median of 6.78. GuruFocus rates XMAD:PHM with a GF Score™ of 86/100 and a GF Value™ of €83.21 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,256 Biotechnology companies, Pharma Mar ranks better than 94.9% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pharma Mar's annualized net income for the quarter that ended in Mar. 2026 was €6.1 Mil. Pharma Mar's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was €250.8 Mil. Therefore, Pharma Mar's annualized ROE % for the quarter that ended in Mar. 2026 was 2.45%.
The historical rank and industry rank for Pharma Mar's ROE % or its related term are showing as below:
XMAD:PHM'
s ROE % Range Over the Past 10 Years
Min: -69.5 Med: 6.78 Max: 240.61
Current: 34.78
During the past 13 years, Pharma Mar's highest ROE % was 240.61%. The lowest was -69.50%. And the median was 6.78%.
XMAD:PHM's ROE % is ranked better than 94.9% of 1256
companies
in the Biotechnology industry
Industry Median: -38.26
vs XMAD:PHM: 34.78
Pharma Mar (XMAD:PHM) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Pharma Mar ROE % Related Terms
Pharma Mar ROE % Historical Data
* Premium members only.
The historical data trend for Pharma Mar's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pharma Mar's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Mar ROE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Mar's ROE % distribution charts can be found below:
* The bar in red indicates where Pharma Mar's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Pharma Mar (XMAD:PHM) has a ROE % of 2.45% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pharma Mar and its competitors. This is 64% below median its historical median of 6.78. According to the industry distribution chart, Pharma Mar ranks #64 out of 1256 companies in the Biotechnology industry, placing it in the top 5.1%.
Is Pharma Mar's ROE % too high?
Pharma Mar's current ROE % of 2.45% is 64% below median its 10-year median of 6.78. Based on the distribution chart, Pharma Mar ranks #64 out of 1256 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharma Mar has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's ROE % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Mar ranks #64 out of 1256 companies for ROE %. This places Pharma Mar in the top 5% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pharma Mar and its competitors. Pharma Mar's current ROE % is 2.45%, which is 64% below median its own 10-year median of 6.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (XMAD:PHM) is currently considered Modestly Undervalued. The stock's GF Value™ is €83.21, compared to a current price of €72.90 — trading 12.4% below its estimated fair value. The current ROE % is 2.45%, which is 64% below median its 10-year median of 6.78. Pharma Mar's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pharma Mar (XMAD:PHM), the current ROE % is 2.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharma Mar (XMAD:PHM) Overvalued in 2026?
Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued.
The current stock price of €72.90 is trading 12.4% below its estimated GF Value™ of €83.21.
GuruFocus considers Pharma Mar to be Modestly Undervalued.
Key valuation signals for XMAD:PHM:
ROE %: 2.45% (64% below median its 10-year median of 6.78)
GF Value™: €83.21 vs. price of €72.90 (12.4% below fair value)
No single metric tells the full story. See the XMAD:PHM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
86GF Score
Get the complete analysis for XMAD:PHM
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:PHM has been successfully added to your 
